LT3762380T - Fenilpirolidinono formilpeptido 2 receptoriaus antagonistai - Google Patents

Fenilpirolidinono formilpeptido 2 receptoriaus antagonistai

Info

Publication number
LT3762380T
LT3762380T LTEPPCT/US2019/020493T LTUS2019020493T LT3762380T LT 3762380 T LT3762380 T LT 3762380T LT US2019020493 T LTUS2019020493 T LT US2019020493T LT 3762380 T LT3762380 T LT 3762380T
Authority
LT
Lithuania
Prior art keywords
phenylpyrolidinone
formilpeptido
receptor antagonists
antagonists
receptor
Prior art date
Application number
LTEPPCT/US2019/020493T
Other languages
English (en)
Lithuanian (lt)
Inventor
Pravin Sudhakar Shirude
Vishweshwaraiah BALIGAR
Balaji SESHADRI
Amit Kumar Chattopadhyay
Wurtz
Ellen K. Kick
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of LT3762380T publication Critical patent/LT3762380T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/304—Aromatic acids (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
LTEPPCT/US2019/020493T 2018-03-05 2019-03-04 Fenilpirolidinono formilpeptido 2 receptoriaus antagonistai LT3762380T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862638556P 2018-03-05 2018-03-05
PCT/US2019/020493 WO2019173182A1 (en) 2018-03-05 2019-03-04 Phenylpyrrolidinone formyl peptide 2 receptor agonists

Publications (1)

Publication Number Publication Date
LT3762380T true LT3762380T (lt) 2022-02-25

Family

ID=65812419

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2019/020493T LT3762380T (lt) 2018-03-05 2019-03-04 Fenilpirolidinono formilpeptido 2 receptoriaus antagonistai

Country Status (30)

Country Link
US (3) US10676431B2 (enExample)
EP (2) EP3981767A1 (enExample)
JP (1) JP7155276B2 (enExample)
KR (1) KR102803660B1 (enExample)
CN (1) CN111868052B (enExample)
AR (1) AR114429A1 (enExample)
AU (1) AU2019232704B2 (enExample)
BR (1) BR112020017744A2 (enExample)
CA (1) CA3092927A1 (enExample)
CL (1) CL2020002224A1 (enExample)
CY (1) CY1124985T1 (enExample)
DK (1) DK3762380T3 (enExample)
EA (1) EA202092094A1 (enExample)
ES (1) ES2904483T3 (enExample)
HR (1) HRP20220118T1 (enExample)
HU (1) HUE058044T2 (enExample)
IL (1) IL277044B2 (enExample)
LT (1) LT3762380T (enExample)
MX (1) MX2020009000A (enExample)
MY (1) MY204384A (enExample)
PE (1) PE20210046A1 (enExample)
PL (1) PL3762380T3 (enExample)
PT (1) PT3762380T (enExample)
RS (1) RS62833B1 (enExample)
SG (1) SG11202008504SA (enExample)
SI (1) SI3762380T1 (enExample)
SM (1) SMT202200067T1 (enExample)
TW (1) TWI804585B (enExample)
WO (1) WO2019173182A1 (enExample)
ZA (1) ZA202006115B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018005756A (es) * 2015-11-24 2018-08-01 Squibb Bristol Myers Co Ubicacion como objetivo del receptor 2 de formilo-peptido/receptor de lipoxina a4 (fpr2/alx) para el tratamiento de enfermedades cardiacas.
US11180490B2 (en) 2017-06-09 2021-11-23 Bristol-Myers Squibb Company Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists
JP7088965B2 (ja) 2017-06-09 2022-06-21 ブリストル－マイヤーズ スクイブ カンパニー アリール複素環ピペリジノンホルミルペプチド２受容体およびホルミルペプチド１受容体アゴニスト
WO2018227058A1 (en) * 2017-06-09 2018-12-13 Bristol-Myers Squibb Company Piperidinone formyl peptide 2 receptor agonists
KR102623473B1 (ko) * 2017-06-09 2024-01-09 브리스톨-마이어스 스큅 컴퍼니 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제
EA202092094A1 (ru) 2018-03-05 2020-12-10 Бристол-Маерс Сквибб Компани Фенилпирролидиноновые агонисты формилпептидного рецептора 2
KR102656571B1 (ko) 2018-03-05 2024-04-11 아르커스 바이오사이언시즈 인코포레이티드 아르기나아제 억제제
CN113166134B (zh) 2018-11-26 2024-06-14 百时美施贵宝公司 作为甲酰肽2受体激动剂的吡咯烷酮衍生物
ES2946673T3 (es) * 2019-06-18 2023-07-24 Bristol Myers Squibb Co Agonistas del FPR2 de óxido de biaril dialquil fosfina
EP4178946A1 (en) * 2020-07-09 2023-05-17 Bristol-Myers Squibb Company Oxopyrrolidine fpr2 agonists
EP4196471A1 (en) * 2020-08-12 2023-06-21 Bristol-Myers Squibb Company Oxopyrrolidine urea fpr2 agonists
EP4281452A4 (en) * 2021-01-21 2024-11-06 Beijing Tiantan Hospital MODULATORS OF FPR1 AND METHODS OF USE THEREOF
US20240300973A1 (en) * 2021-01-21 2024-09-12 Biofront Therapeutics (Beijing) Co., Ltd. Modulators of fpr1 and methods of using the same
EP4074317A1 (en) 2021-04-14 2022-10-19 Bayer AG Phosphorus derivatives as novel sos1 inhibitors
EP4508980A3 (en) 2021-12-15 2025-07-16 Adama Agan Ltd. Compounds useful for the preparation of various agrochemicals and markers thereof
KR20250013176A (ko) 2022-05-27 2025-01-31 아사히 그룹 홀딩스 가부시키가이샤 유산균 유래의 외막 소포를 함유하는 fpr2 작동제
EP4602049A1 (en) 2022-10-13 2025-08-20 Bayer Aktiengesellschaft Sos1 inhibitors
WO2024220453A1 (en) * 2023-04-18 2024-10-24 Bristol-Myers Squibb Company Pyrrolidinone urea fpr2 agonists
WO2024220482A1 (en) * 2023-04-18 2024-10-24 Bristol-Myers Squibb Company Pyrrolidinone urea fpr2 agonists
WO2024220487A1 (en) * 2023-04-18 2024-10-24 Bristol-Myers Squibb Company Carbocyclic phenylpyrrolidinone urea fpr2 agonists
WO2025202955A1 (en) 2024-03-28 2025-10-02 Pi Industries Ltd. Fused bicyclic compounds and their use as pest control agents

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202344A (en) 1990-12-11 1993-04-13 G. D. Searle & Co. N-substituted lactams useful as cholecystokinin antagonists
BR9507838A (pt) 1994-06-02 1997-09-16 Zeneca Ltd Composto processo para preparar o mesmo composição herbicida e processo para danificar severamente ou exterminar plantas não-desejadas
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
TWI354664B (en) * 2003-08-21 2011-12-21 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine rece
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
WO2005047899A2 (en) 2003-11-07 2005-05-26 Acadia Pharmaceuticals Inc. Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation
US7678913B2 (en) * 2004-12-07 2010-03-16 Portola Pharmaceuticals, Inc. Ureas as factor Xa inhibitors
WO2006063293A2 (en) 2004-12-07 2006-06-15 Portola Pharmaceuticals, Inc. THIOUREAS AS FACTOR Xa INHIBITORS
US20070123508A1 (en) 2005-05-27 2007-05-31 Roger Olsson PAR2-modulating compounds and their use
AU2006265835B2 (en) 2005-06-30 2012-05-03 Amgen Inc. Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
TW200831080A (en) 2006-12-15 2008-08-01 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
SI2225231T1 (sl) 2007-12-18 2011-12-30 Actelion Pharmaceuticals Ltd Derivati aminotriazola kot alx agonisti
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US8592454B2 (en) 2008-09-19 2013-11-26 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound and use of same
KR20110117194A (ko) 2009-02-23 2011-10-26 에프. 호프만-라 로슈 아게 암 치료를 위한 신규한 오르토-아미노아미드
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
ES2440790T3 (es) 2009-06-12 2014-01-30 Actelion Pharmaceuticals Ltd. Derivados de oxazol y tiazol como agonistas del receptor del ALX
AU2011270872A1 (en) 2010-06-24 2013-01-31 Allergan, Inc. Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity
JP5917541B2 (ja) 2010-11-17 2016-05-18 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ 架橋スピロ［２．４］ヘプタンエステル誘導体
AU2011336973A1 (en) 2010-12-03 2013-07-11 Allergan, Inc. Pharmaceutical compositions comprising 3,4- dihydroisoquinolin-2(1 H)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity
ES2526132T3 (es) 2010-12-07 2015-01-07 Actelion Pharmaceuticals Ltd. Derivados de oxazolil-metiléter como agonistas del receptor de ALX
KR101847672B1 (ko) 2010-12-07 2018-04-10 이도르시아 파마슈티컬스 리미티드 Alx 수용체 작용제로서의 히드록실화 아미노트리아졸 유도체
CA2827005A1 (en) 2011-02-11 2012-08-16 Allergan, Inc. Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators
US8653299B2 (en) 2011-03-17 2014-02-18 Allergan, Inc. Dihydronaphthalene and naphthalene derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
SI2712358T1 (sl) 2011-05-13 2017-03-31 Array Biopharma, Inc. Spojine pirolidinil sečnine, pirolidinil tiosečnine in pirolidinil gvanidina kot inhibitorji kinaze trka
UA115043C2 (uk) 2011-10-26 2017-09-11 Аллерган, Інк. Амідні похідні n-карбамідзаміщених амінокислот як модулятори формілпептидного рецептора 1 (fprl-1)
US8492556B2 (en) * 2011-11-10 2013-07-23 Allergan, Inc. 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US8541577B2 (en) 2011-11-10 2013-09-24 Allergan, Inc. Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators
KR20140145203A (ko) 2012-04-16 2014-12-22 알러간, 인코포레이티드 포르밀 펩타이드 수용체 2 조절물질로서 (2-우레이도아세트아미도)알킬 유도체
ES2664331T3 (es) 2012-11-13 2018-04-19 Array Biopharma, Inc. Compuestos de N-pirrolidinilo, N'-pirazolilurea, tiourea, guanidina y cianoguanidina como inhibidores de la cinasa Trka
US9790178B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9828360B2 (en) 2012-11-13 2017-11-28 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
CN105377814B (zh) 2013-07-16 2018-04-03 阿勒根公司 作为甲酰基肽受体调节剂的n‑脲取代的氨基酸的衍生物
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
RS57036B1 (sr) * 2013-11-28 2018-05-31 Kyorin Pharmaceutical Co Ltd Urea derivati ili njihove farmakološki prihvatljive soli korisni kao agonisti formil peptidnom receptoru-sličnom 1 (fprl-1)
MX2016007259A (es) 2013-12-03 2016-08-04 Du Pont Pirrolidinonas como herbicidas.
PT3154959T (pt) 2014-05-15 2019-09-24 Array Biopharma Inc 1-((3s,4r)-4-(3-fluorofenil)-1-(2-metoxietil)-pirrolidin-3-il)-3-(4-metil-3-(2-metilpirimidin-5-il)-1-fenil-1h-pirazol-5-il)ureia como inibidor da cinase trka
RU2017129757A (ru) 2015-01-23 2019-02-25 ДжиВиКей БИОСАЕНСЕЗ ПРАЙВИТ ЛИМИТЕД ИНГИБИТОРЫ TrkA КИНАЗЫ
ES2814126T3 (es) * 2015-05-27 2021-03-26 Kyorin Seiyaku Kk Derivado de urea o sal farmacológicamente aceptable del mismo
CN107848962B (zh) 2015-05-27 2021-04-09 杏林制药株式会社 脲衍生物或其药理学上可接受的盐
MX2018005756A (es) 2015-11-24 2018-08-01 Squibb Bristol Myers Co Ubicacion como objetivo del receptor 2 de formilo-peptido/receptor de lipoxina a4 (fpr2/alx) para el tratamiento de enfermedades cardiacas.
JP6811241B2 (ja) * 2015-12-10 2021-01-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ピペリジノンホルミルペプチド受容体２およびホルミルペプチド受容体１アゴニスト
RU2018146946A (ru) 2016-06-08 2020-07-10 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Химические соединения
JP7088965B2 (ja) 2017-06-09 2022-06-21 ブリストル－マイヤーズ スクイブ カンパニー アリール複素環ピペリジノンホルミルペプチド２受容体およびホルミルペプチド１受容体アゴニスト
US11180490B2 (en) 2017-06-09 2021-11-23 Bristol-Myers Squibb Company Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists
KR102623473B1 (ko) 2017-06-09 2024-01-09 브리스톨-마이어스 스큅 컴퍼니 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제
WO2018227058A1 (en) 2017-06-09 2018-12-13 Bristol-Myers Squibb Company Piperidinone formyl peptide 2 receptor agonists
EA202092094A1 (ru) 2018-03-05 2020-12-10 Бристол-Маерс Сквибб Компани Фенилпирролидиноновые агонисты формилпептидного рецептора 2

Also Published As

Publication number Publication date
CL2020002224A1 (es) 2020-11-20
EP3762380B1 (en) 2021-12-15
IL277044A (en) 2020-10-29
JP7155276B2 (ja) 2022-10-18
US20200255375A1 (en) 2020-08-13
KR20200128709A (ko) 2020-11-16
BR112020017744A2 (pt) 2020-12-22
SMT202200067T1 (it) 2022-03-21
RS62833B1 (sr) 2022-02-28
SG11202008504SA (en) 2020-10-29
HUE058044T2 (hu) 2022-06-28
EP3981767A1 (en) 2022-04-13
MX2020009000A (es) 2020-10-05
ES2904483T3 (es) 2022-04-05
US10676431B2 (en) 2020-06-09
CY1124985T1 (el) 2023-01-05
AU2019232704A1 (en) 2020-10-22
EA202092094A1 (ru) 2020-12-10
EP3762380A1 (en) 2021-01-13
MY204384A (en) 2024-08-27
KR102803660B1 (ko) 2025-05-02
AU2019232704B2 (en) 2024-03-21
DK3762380T3 (da) 2022-01-17
PL3762380T3 (pl) 2022-02-21
TW202000645A (zh) 2020-01-01
PT3762380T (pt) 2022-01-25
WO2019173182A1 (en) 2019-09-12
US11708327B2 (en) 2023-07-25
US11117861B2 (en) 2021-09-14
ZA202006115B (en) 2022-06-29
IL277044B2 (en) 2023-10-01
CN111868052B (zh) 2024-03-08
US20190270704A1 (en) 2019-09-05
CA3092927A1 (en) 2019-09-12
SI3762380T1 (sl) 2022-09-30
US20210371378A1 (en) 2021-12-02
IL277044B1 (en) 2023-06-01
HRP20220118T1 (hr) 2022-04-15
AR114429A1 (es) 2020-09-02
TWI804585B (zh) 2023-06-11
CN111868052A (zh) 2020-10-30
JP2021516240A (ja) 2021-07-01
PE20210046A1 (es) 2021-01-08

Similar Documents

Publication Publication Date Title
LT3762380T (lt) Fenilpirolidinono formilpeptido 2 receptoriaus antagonistai
EP3697759A4 (en) MUSCARINIAN ACETYLCHOLINE RECEPTOR ANTAGONISTS M4
EP4069686C0 (en) GLP-1 RECEPTOR AGONIST
EP3814381A4 (en) TRI-SPECIFIC ANTAGONISTS
DK3820873T3 (da) Selektive østrogenreceptornedbrydere
EP3860977A4 (en) INTEGRIN ANTAGONISTS
EP3344295A4 (en) CHIMERIC ANTI-SIALYL TN ANTIGEN RECEPTORS
EP3651762A4 (en) MUSCARINIAN ACETYLCHOLINE RECEPTOR ANTAGONISTS M4
DK3713928T3 (da) Hidtil ukendte bradykinin-b2-receptorantagonister
EP3630763A4 (en) CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS
EP3703680A4 (en) MUSCARINIAN ACETYLCHOLINE RECEPTOR ANTAGONISTS M4
EP3732163A4 (en) MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS
EP3806903A4 (en) CD79A CHIMERIC ANTIGEN RECEPTORS
DK3820874T3 (da) Selektive estrogenreceptornedbrydere
EP3628005A4 (en) Corticotropin releasing factor receptor antagonists
EP3846806A4 (en) Muscarinic acetylcholine m1 receptor antagonists
EP3746421A4 (en) MUSCARIN ACETYLCHOLIN M4 RECEPTOR ANTAGONISTS
PL3613739T3 (pl) Antagoniści integryn
EP3697781A4 (en) MUSCARINIAN ACETYLCHOLINE RECEPTOR ANTAGONISTS M4
EP4069708A4 (en) Sstr5 antagonists
EP3762386A4 (en) ADENOSINE RECEPTOR ANTAGONISTS AND THEIR USES
IL279960A (en) P2X3 receptor antagonists
EP3665175A4 (en) MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS
EP3684359C0 (en) TRPV2 ANTAGONISTS
IL264262A (en) Anti-il-22r antibodies